Advances in Immunotherapy in Esophagogastric Cancer

Khalid Jazieh; Harry Yoon; Mojun Zhu

doi:10.1016/j.hoc.2024.02.002

Advances in Immunotherapy in Esophagogastric Cancer

Hematol Oncol Clin North Am. 2024 Jun;38(3):599-616. doi: 10.1016/j.hoc.2024.02.002. Epub 2024 Mar 15.

Authors

Khalid Jazieh¹, Harry Yoon², Mojun Zhu²

Affiliations

¹ Division of Medical Oncology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA. Electronic address: jazieh.khalid@mayo.edu.
² Division of Medical Oncology, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.

PMID: 38493074
DOI: 10.1016/j.hoc.2024.02.002

Abstract

Immune checkpoint inhibitors are rapidly transforming the care of patients with esophagogastric cancer. Particularly, anti-PD-1 therapy has demonstrated promising efficacy in metastatic and resectable disease. In this review, the authors discuss landmark clinical trials, highlight challenges and opportunities in this field, and propose potential directions for future work.

Keywords: Cancer; Esophageal; Gastroesophageal; Immune checkpoint inhibitor; Immunotherapy; Malignancy; PD-1; PD-L1.

Publication types

Review

MeSH terms

Clinical Trials as Topic
Esophageal Neoplasms* / immunology
Esophageal Neoplasms* / therapy
Humans
Immune Checkpoint Inhibitors* / therapeutic use
Immunotherapy* / methods
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Programmed Cell Death 1 Receptor / immunology
Stomach Neoplasms* / immunology
Stomach Neoplasms* / therapy

Substances

Immune Checkpoint Inhibitors
Programmed Cell Death 1 Receptor
PDCD1 protein, human